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Opioid-induced hyperalgesia
Abstract
Recently it became clear that opioids, besides their role in analgesia, mayalso induce hyperalgesia. Some-
thing what in the past was called opioidneurotoxicity. Hyperalgesia, or hypersensitivity to pain stimuli may
berelated to well known problems of tolerance to opioids. Hyperalgesia is amajor clinical problem and its
recognition and treatment are of paramountimportance. It is believed that uncoupling of opioid receptors
from theGi/Go proteins and coupling them to Gs protein changes dramatically activityof opioid receptors. In
this article the different aspects of diagnosis andtreatment of hyperalgesia are discussed.
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Introduction
Opioid use has been increasing in recent years.
The changing pattern in opioid use has resulted in
the emergence of neurotoxicity as a major adverse
effect of the treatment of cancer pain [1]. As a con-
sequence, the incidence of neuroexcitatory adverse
effects, including hyperalgesia, allodynia, myoclo-
nus, seizures, in patients administered large doses
of systemic morphine or its structural analogues to
relieve uncontrolled cancer pain, has been incre-
asing in recent years.
The problem of hyperalgesia, tolerance, and no-
ciception remains not clearly understood and quite
difficult to interpret in the clinical setting of cancer
patients, where multiple factors are able to con-
found the picture [2]. These conditions are difficult
to identify and controversies exist about the real
occurrence of this phenomenon in clinical setting [3, 4].
Clinical considerations
Clinical reports suggest that opioids, intended to
abolish pain, can unexpectedly produce abnormally
heightened pain sensations, which are characteri-
zed by a lowering of the pain threshold, commonly
known as hyperalgesia [5]. Such abnormal sensa-
tions have been described as being quantitatively
different from normal pain sensation and differen-
tially localized from the site of the original pain
complaint. This could result in the exacerbation ra-
ther than the attenuation of excitatory behaviours.
It is possible to hypothesize an iatrogenic syn-
drome characterized initially by a declining analge-
sia, requiring further opioid escalation to maintain
the previous level of analgesia — a worsening of
pain and whole-body hyperalgesia (panalgesia) often
associated with cognitive disturbances, delirium,
agitation ranging to screaming in agony, grand mal
seizures and multifocal myoclonus. Alternately, pa-
tients on opioid therapy, who present long periods
of breakthrough nociception due to an inadequate
dosage, may require an aggressive treatment with
increasing opioid doses. After an initially favourable
response, they could develop a hyperexcitated state
worsened by further dose increments. The thera-
peutic difficulties paradoxically stay in accepting the
widespread concept of morphine as a pure agonist,
with a linear dose-response curve expressed as the
more pain, the more drug. Of interest, there are
considerable data emphasizing that morphine is not
a full agonist, but that it can produce a partial ago-
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nist effect with an increased stimulus [6]. This may
correspond to a therapeutic paradox where the con-
sequence (increasing pain), is treated favouring its
cause (opioid escalation).
A metabolic explanation has been reported to
explain this phenomenon, the ratio of morphine
metabolites being altered in favour of inactive, or
even antagonistic, morphine-3-glucuronide. Opio-
ids and other neurotoxic agents, including morphi-
ne 3 glucuronide, through a non-opioid receptor
mediated mechanism, may mimic the antiglyciner-
gic effects of strychnine, although other authors,
using a different experimental paradigm, have re-
ported that acute M3G (given in a ratio 4:1) admini-
stration increases the acute antinociceptive effects
of morphine, presumably by product inhibition of
substrate metabolism [7]. The final effect could be
dependent on the amount of M3G passing the blood
brain barrier. Renal failure may predispose to the
syndrome, producing an accumulation of morphine
metabolites. On the other hand, all opioid analge-
sics probably have convulsant activity when admini-
stered in sufficiently high doses, as hyperalgesia has
been reported to occur even with increasing doses
of methadone.
Although much experimental data exist to expla-
in these clinical changes of opioid response, no data
exist on how, when and why this occurs, or if it is
a simple consequence of a rapid derangement of the
central nervous system, possibly occurring in the last
days of life. Nevertheless, experimental models provi-
de new information and hypothesis, which may help
in understanding some difficult clinical conditions.
Biochemical changes associated
with hyperalgesia
In recent years, experimental and clinical studies
have pointed out the possible autonomous hyperal-
gesic effect of high doses of opioids. More recently,
it has been recognized that tolerance can develop
rapidly from chronic as well as acute opioid exposu-
re. Spinal morphine has been associated with para-
doxical algesia and hyperesthesia, which were nalo-
xone-insensitive (8). Similar observations have been
reported for hyperalgesia. Rapid development of
tolerance and hyperalgesia, normally considered as
independent unrelated phenomena, share some
common biochemical mechanisms [9], even in acu-
te conditions. Intense opioid receptor activation, such
as that occurring with short-lived opioid remifenta-
nyl overdosing, induces rapid and extensive toleran-
ce which has been shown in humans and perhaps
manifesting as dramatic hyperalgesia [10].
The development of tolerance and hyperalgesic
states involves the activation of excitatory glutama-
te receptors at the N-methyl-D-aspartate (NMDA)
type in the central nervous system. After repeated
high intensity noxious stimulation, NMDA receptor
activation initiates an intracellular cascade, princi-
pally consisting in an increase of intracellular cal-
cium concentration, activation of protein kinase (PKC)
and the calcium-calmodulin-mediated production of
nitric oxide (NO). Increases in membrane-bound PKC
occurring in spinal cord have been shown to positi-
vely correlate with the degree of hyperalgesia. The
expression of NO-synthases is upregulated after dif-
ferent series of painful stimuli, and NO release con-
tributes to secondary hyperalgesia and allodynia.
Being a highly diffusible molecule, NO is believed to
be an important messenger in signal transduction
pathways that enhance nociceptive transmission in
the central nervous system. NO synthase inhibitors
can reverse hyperalgesia induced by nerve injury and
result in the prevention or retardation of the deve-
lopment of opioid tolerance [7].
On the other hand, a series of studies suggest
cross-talk between opioid receptors and NMDA re-
ceptors. Opioid receptor activation may result in
stimulation of protein kinase C (PKC), an enzyme
that phosphorylates several target proteins, inclu-
ding NMDA receptors. Phosphorilation of this re-
ceptor results in a release of the Mg++ block, en-
try of calcium in the cell, and activation of a series
of cascades that can lead to opioid receptor down-
-regulation (opioid tolerance) and hyper-responsi-
veness (underlying hyperalgesia). The final cascade
of this process induces the synthesis of nitrous oxi-
de (NO), moreover, NO “per se” can alter the level
of expression of opioid receptors in immunocytes
[11]. Alternately, activated glia cells (these also of
hematologic origin), could be implicated in the ge-
nesis of morphine tolerance, and it has been hypo-
thesized that they could release substances that
create situations of exaggerated pain such as allo-
dynia, hyperalgesia, morphine resistance or toler-
ance [12].
A feature of both nerve-injury pain and opioid-
-induced hyperalgesia is an increased spinal dynor-
phin. It has been demonstrated that abnormal pain
and decreased opioid antinociception seen after su-
stained opioid exposure is mediated by spinal dy-
norphin. Spinal dynorphin content was elevated after
opioid infusion, suggesting that opioids can regula-
te the expression of spinal dynorphin, probably as
a result of opioid occupation. The over-expression
of spinal dynorphin is also likely to have consequen-
ces on the release of excitatory neurotransmitters,
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such as substance P. The effects of dynorphin anti-
serum parallel those seen with NMDA-antagonist
MK-801 and suggest that dynorphin may interact,
directly or indirectly, with the NMDA receptor [13].
Opioids, opioid antagonists
and opioid-induced hyperalgesia
There is a significant variability among opioid
drugs in inducing rapid endocytosis of opioid recep-
tors. This is an independent functional property that
distinguishes clinically important analgesic drugs
such as morphine and methadone. It is associated
with functional desensibilization of receptor-media-
ted signal transduction, which is implicated in the
development of tolerance and dependence [14].
Cellular signs of tolerance are due to sustained acti-
vation of supersensitized excitatory opioid receptor
functions. Activation of Gs-coupled opioid recep-
tors on sensory neurons elicits stimulatory effects
via an adenylate cyclase/cyclic AMP/protein kinase
A-mediated transduction system, which thereby at-
tenuates inhibitory effects mediated by concomi-
tant activation of Gi/Go-coupled opioid receptors
on these cells. Opioid receptors can be rapidly inter-
converted between inhibitory Gi/Go-coupled and
excitatory Gs-coupled modes following alterations
in the concentrations of a specific glycolipid, GM1
ganglioside, abundantly distributed on the surface
of neuronal cell membranes. This dynamic plasticity
provides a cellular mechanism that may underlie
modulation of upload analgesia, tolerance, or hyper-
algesia [15]. Opioid tolerance is mediated not only
by up-regulation of the well known Gs/AC/cAMP/
/PKA second messenger system, but also by eleva-
tion of GM1 ganglioside following activation of the
cAMP/PKA-dependent glycosyltransferase that syn-
thesize GM1. Elevation of GM1 by sustained activa-
tion of Gs-coupled opioid receptor functions may
increase the conversion of opioid receptors from
the inhibitory to excitatory Gs-coupled mode, resul-
ting in an increased efficacy of coupling of Gs-co-
upled opioid receptors to the AC/cAMP transducer
system, and consequently in supersensitized excita-
tory opioid receptors.
Recent data have offered further interesting
advances in the knowledge of these biochemical
processes. A remarkably low concentration of mor-
phine may mediate excitatory Gs-coupled opioid
receptor effects, which may provide insights into
the mechanisms underlying opioid hyperalgesia,
or anti-analgesia. Low concentrations of antago-
nist opioids have been found to have selective
antagonist actions on excitatory, but not inhibito-
ry, opioid receptor-mediated function in dorsal
root ganglion neurons. Thus, a direct competitive
antagonism of Gs-coupled excitatory opioid re-
ceptor functions by co-treatment with extremely
low doses of clinically available opioid antagoni-
sts, e.g. naloxone markedly enhances morphine’s
analgesic potency and simultaneously attenuates
opioid tolerance and dependence [15]. These ob-
servations are in contrast to traditional opioid
pharmacology concepts, which fail to acknowled-
ge that morphine or other opioid agonists can
activate opioid receptors distributed in both exci-
tatory Gs-coupled as well as inhibitory Gi/Go-co-
upled modes on nociceptive neurons.
Hyperalgesia as a consequence
of inappropriate opioid treatment
Although a continuous exposure to opioids has
been recognized to induce analgesic tolerance and
abnormal pain, a real opioid-induced hyperalgesia
is exceptionally present in opioid addicts. It has
been hypothesized that these conditions are de-
pendent on a compensatory neuronal activity con-
sequent to intermittent withdrawal crisis, rather
than to opioid escalation per se [16]. Thus, the
growing evidence of an abnormal response to opio-
ids in cancer patients, where a withdrawal syndro-
me can be excluded, can be explained, for example,
as an inappropriate opioid administration leaving
periods of poor pain control (breakthrough anal-
gesia). Inadequate opioid receptor occupancy has
been found to produce breakthrough pain, indu-
ced by spinal glutamate release, independent of
small afferent input, as in neuropathic pain, contri-
buting to an enhanced loss of opioid receptor func-
tion [17]. Clinically, this condition may be reprodu-
ced with prolonged periods of uncontrolled pain
between dose increases.
Hyperalgesia and tumours
The presence of opioid receptors in tumorous cells
and the possible opioid trapping mimicking toleran-
ce [18] offer new fascinating insights to explain the
response to opioids in cancer patients. Opioid recep-
tor subtypes are expressed in human surgical speci-
mens of both normal and non-small cell lung cancer.
The role of opioid receptor in tumour cells could be
minimal after receptor saturation, but nitric oxide
(NO) release is mediated through these receptors and
morphine-stimulated NO release is significantly hi-
gher and prolonged than in normal lung [19]. This
could create conditions for persistent hyperalgesia.
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Methods to counteract opioid-induced
hyperalgesia
In escalating opioid doses rapidly recognition of
the development of hyperalgesia should be suspec-
ted, as higher doses of opioids may stimulate rather
than inhibiting the central nervous system, with dif-
ferent mechanisms, well recognized in experimental
studies. Alternative procedures should be taken into
consideration to break this vicious circle before pain
conditions worsen irreversibly.
Opioid switching is increasingly used in patients
with a poor opioid response. The presumed offen-
ding drug should be stopped, and a rapid opioid
substitution should be started [20]. Of concern, while
opioid switching often reserves particular cautions,
particularly when switching to methadone, the mat-
ter is even more complex, in patients who are pre-
senting increasing pain with increasing opioid do-
ses, as antinociception cannot be clearly distin-
guished from hyperalgesia, and the simple disconti-
nuation of the offending opioid may produce a re-
duction in pain intensity. Regardless of the different
modalities proposed in literature, all these calcula-
tions do not take into account the modality of the
previous opioid escalation from a dynamic point of
view, that is the short time used to increase the
dose, or other causes as the driving force for opioid
escalation, for example the development of opioid-
-induced hyperalgesia. Of course, the exact thre-
shold between antinociception and hyperalgesia is
un-known and impossible to determine. Thus, star-
ting doses should be lower than expected, even when
using an approach of doses inversely proportional
to the previous dose. Possibly, a patient controlled
analgesia [2], according to the patient’s response
and careful clinical monitoring, would be an effecti-
ve and safe alternative, as dosing is clinically media-
ted in some way, regardless of possible calculations,
which are unreliable in such clinical situations.
There are some reports in literature which could
be interpreted in the light of more recent knowled-
ge regarding opioid-induced hyperalgesia. At some
levels of opioid doses associated with tolerance and
hyperalgesia, it is impossible quantify any approxi-
mate dose conversion rate. For example it has been
reported that only 1% of the equianalgesic dose of
the prior opioid, which was parenteral morphine in
doses of 21.600 mg/day. Such megadoses of opio-
ids have been the subject of controversy as they
could be prevented by using other available me-
thods or route of administration. It is likely that
patients receiving grams of parenteral morphine, or
any other opioid, may have a prevalent hyperalgesic
component, so that the elimination of the first opio-
id per se implicates a consequent reduction of the
state of hyperexcitation, to a level of “nociception”
attributable to a meaningfully actual painful input,
which requires doses even lower than expected with
any prudent conversion ratio.
New research areas
In cancer pain treated with opioids, there is di-
scharge of afferent c-fibres, set off by the cancer
injury, directly or indirectly, causing a state of cen-
tral sensitisation. The development of hyperalgesia
and the rightward shift of opioid antinociceptive
dose-response curve were prevented by the admini-
stration of NMDA receptor antagonists. NMDA an-
tagonists do not affect the initial fast synaptic trans-
mission in dorsal horn neurons but selectively inhi-
bit the increase in neural responses to successive
stimuli. Thus, ketamine per se produces only a week
analgesic effect, but significantly influences central
hyperexcitability and inhibits wind-up in dorsal horn
neurons. Ketamine has been reported to improve
analgesia in patients with uncontrolled pain rece-
iving high doses of opioids administered by diffe-
rent routes. Experimental studies have shown that
single doses of a NMDA antagonist may reduce hy-
peralgesia but not enhance morphine antinocicep-
tion. Ketamine, a non-competitive NMDA antago-
nist, has been shown to inhibit wind-up in wide
range neurons and to be involved in central tempo-
ral summation and central sensitisation. Ketamine
may act predominantly by reversing morphine tole-
rance and/or opioid-induced hyperalgesia, as the
blockade of NMDA receptors does not change base-
line nociceptive response to painful stimulation or
baseline spontaneous pain, and NMDA receptor an-
tagonists per se are unlikely to act as analgesics.
They are most likely to reduce the gain of pain in-
tensity rather than removing the normal pain re-
sponse, although in a clinical setting is quite diffi-
cult to differentiate an antihyperalgesic and antino-
ciceptive effect. It has been suggested that intermit-
tently administered ketamine would bring about
a more long-term reversal of the central changes
[21]. With these experimental observations in mind,
a clinical approach with pulse ketamine could be
effective in reversing opioid tolerance in patients
taking high doses of opioids, who are potentially at
risk for future adverse effects.
The use of substances able to reverse hyperalge-
sia while interrupting this process at the spinal cord
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level could also be helpful. Local anaesthetics, used
in combination with low doses of opioids intrathe-
cally, are of paramount importance in patients pre-
senting increasing pain with escalating doses of opio-
ids. Other than providing analgesia with a different
mechanism, local anaesthetics may offer further
advantages. Subtypes of sodium channel are diffe-
rentially expressed in sensory neurons in the presen-
ce of continuous and high intensity discharges from
nerve or tissue injury. It has been observed that
constant nerve depolarisation increases the potency
of local anaesthetic block and could preferentially
block certain subtypes of sodium channels involved
in injury-induced pathologic depolarization, witho-
ut affecting the sodium channels involved in normal
signalling [22].
In vitro and in vivo studies have demonstrated
that direct competitive antagonism of Gs-coupled
excitatory opioid receptor functions by co-treatment
with extremely low doses of naloxone markedly en-
hances morphine’s analgesic potency and simulta-
neously attenuates opioid tolerance and dependen-
ce. Excitation would produce hyperalgesia or tole-
rance, whereas inhibition would produce typical
opioid effects. Anti-hyperalgesic effects have been
found even with low receptor concentrations of opio-
ids in a recent experimental bimodal means of opio-
id receptor activity. This kind of modulation of the
action potential of nociceptive neurons appears to
be mediated by activation of GM1-regulated inter-
convertible opioid receptors that can occur either in
an inhibitory mode or in an excitatory mode. These
modes seems to be induced by higher (mcg) and
lower opioid concentrations (pM range), respective-
ly. Selective blockade of excitatory opioid effects in
neurons by co-treatment with pM doses of naloxo-
ne has been found to attenuate the “anti-analge-
sic” effects of opioid agonists and thereby enhance
their “analgesic” efficacy. The inhibitory mode, le-
ading to inhibitory effects, that is “analgesia”, is
blocked by relatively high doses of naloxone (nM
range) [23].
Conclusions
Although the problem of hyperalgesia, toleran-
ce, and nociception remains not clearly understood
and quite difficult to interpret in the clinical setting
of cancer patients, where multiple factors are able
to confound the picture, the integration of basic
knowledge and clinical aspects may help assist clini-
cians to apply specific alternative approaches in
daily activities when such difficult conditions occur.
In escalating opioid doses rapidly recognition
of the development of hyperalgesia should be
suspected, as higher doses of opioids may stimu-
late rather than inhibit the central nervous sys-
tem, with different mechanisms, well recognized
in experimental studies. Alternative procedures
should be taken into consideration to break this
vicious circle before pain conditions worsen irre-
versibly. More data are needed to detect these
conditions early, as actually no diagnostic infor-
mation on specific markers, clinical or biochemi-
cal, exists and most cases are individuated a po-
steriori, given the rapidity of the events in such
conditions.
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